Nightstar Therapeutics (Nightstar Therapeutics) Common Stock : $0.06 Mil (As of Mar. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Nightstar Therapeutics Common Stock?

Nightstar Therapeutics's quarterly common stock increased from Sep. 2018 ($0.00 Mil) to Dec. 2018 ($0.06 Mil) but then stayed the same from Dec. 2018 ($0.06 Mil) to Mar. 2019 ($0.06 Mil).

Nightstar Therapeutics's annual common stock increased from Dec. 2016 ($0.00 Mil) to Dec. 2017 ($0.00 Mil) and increased from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($0.06 Mil).

Nightstar Therapeutics Common Stock Historical Data

The historical data trend for Nightstar Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nightstar Therapeutics Common Stock Chart

Nightstar Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Common Stock

0.06

Nightstar Therapeutics Quarterly Data
	Dec15	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
Common Stock	Get a 7-Day Free Trial						-	-	-	0.06	0.06

Nightstar Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Nightstar Therapeutics (Nightstar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nightstar Therapeutics PLC (NAS:NITE) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 Euston Road, London, GBR, NW1 2BE

Website

http://www.nightstartx.com

Nightstar Therapeutics Ltd is a clinical-stage gene therapy company. It is focused on developing and commercializing a pipeline of novel and potentially curative, one-time retinal gene therapies for patients suffering from rare inherited retinal diseases. The company's retinal gene therapy product candidate, NSR-REP1, is being developed for the treatment of choroideremia, a rare, degenerative, X-linked genetic retinal disorder primarily affecting males that is caused by a mutation in the CHM gene.

Executives

Nea 15 Gp, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Gregory Scott Robinson	officer: Chief Scientific Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
James G Mcarthur	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram	officer: Chief Financial Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Tuyen Ong	officer: Chief Development Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Paula K Cobb	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott M Whitcup	director	2525 DUPONT DRIVE, IRVINE CA 92612
Scott D Sandell	10 percent owner
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett	10 percent owner